{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:02:54Z","timestamp":1793278974513,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T00:00:00Z","timestamp":1754784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T00:00:00Z","timestamp":1754784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00198-025-07647-2","type":"journal-article","created":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T08:26:48Z","timestamp":1754814408000},"page":"1711-1718","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Bone mineral density changes following immune checkpoint inhibitor therapy: insights from a case series analysis"],"prefix":"10.1007","volume":"36","author":[{"given":"Vasiliki","family":"Siampanopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios C.","family":"Ziogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Lyrarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Anastasopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0906-3617","authenticated-orcid":false,"given":"Anna","family":"Angelousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,10]]},"reference":[{"issue":"2","key":"7647_CR1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"issue":"6","key":"7647_CR2","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-22-0689","volume":"187","author":"ES Husebye","year":"2022","unstructured":"Husebye ES, Castinetti F, Criseno S, Curigliano G, Decallonne B, Fleseriu M, Higham CE, Lupi I, Paschou SA, Toth M, van der Kooij M, Dekkers OM (2022) Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol 187(6):G1\u2013G21. https:\/\/doi.org\/10.1530\/EJE-22-0689","journal-title":"Eur J Endocrinol"},{"issue":"15","key":"7647_CR3","doi-asserted-by":"publisher","first-page":"6585","DOI":"10.1002\/cam4.2533","volume":"8","author":"E Kassi","year":"2019","unstructured":"Kassi E, Angelousi A, Asonitis N, Diamantopoulos P, Anastasopoulou A, Papaxoinis G, Kokkinos M, Giovanopoulos I, Kyriakakis G, Petychaki F, Savelli A, Benopoulou O, Gogas H (2019) Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma. Cancer Med 8(15):6585\u20136594. https:\/\/doi.org\/10.1002\/cam4.2533","journal-title":"Cancer Med"},{"issue":"2","key":"7647_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/diseases12020040","volume":"12","author":"A Angelousi","year":"2024","unstructured":"Angelousi A, Ziogas DC, Siampanopoulou V, Mytareli C, Anastasopoulou A, Lyrarakis G, Gogas H (2024) Reaching the diagnosis of checkpoint inhibitor-induced diabetes mellitus in different clinical scenarios: a real-world application of updated diagnostic criteria. Diseases 12(2):40. https:\/\/doi.org\/10.3390\/diseases12020040","journal-title":"Diseases"},{"issue":"7","key":"7647_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072016","volume":"15","author":"C Mytareli","year":"2023","unstructured":"Mytareli C, Ziogas DC, Karampela A, Papalexis P, Siampanopoulou V, Lafioniatis A, Benopoulou O, Gogas H, Angelousi A (2023) The uncharted landscape of rare endocrine immune-related adverse events. Cancers (Basel) 15(7):2016. https:\/\/doi.org\/10.3390\/cancers15072016","journal-title":"Cancers (Basel)"},{"issue":"4","key":"7647_CR6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00198-023-06690-1","volume":"34","author":"C Ye","year":"2023","unstructured":"Ye C, Lee K, Leslie WD, Lin M, Walker J, Kolinsky M (2023) Fracture rate increases after immune checkpoint inhibitor treatment: a potential new immune related adverse event. Osteoporos Int 34(4):735\u2013740. https:\/\/doi.org\/10.1007\/s00198-023-06690-1","journal-title":"Osteoporos Int"},{"issue":"1","key":"7647_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40425-018-0417-8","volume":"6","author":"KF Moseley","year":"2018","unstructured":"Moseley KF, Naidoo J, Bingham CO, Carducci MA, Forde PM, Gibney GT, Lipson EJ, Shah AA, Sharfman WH, Cappelli LC (2018) Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series. J Immunother Cancer 6(1):104. https:\/\/doi.org\/10.1186\/s40425-018-0417-8","journal-title":"J Immunother Cancer"},{"issue":"3","key":"7647_CR8","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/ijc.33592","volume":"149","author":"DM Filippini","year":"2021","unstructured":"Filippini DM, Gatti M, Di Martino V, Cavalieri S, Fusaroli M, Ardizzoni A, Raschi E, Licitra L (2021) Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: case series and large-scale pharmacovigilance analysis. Int J Cancer 149(3):675\u2013683. https:\/\/doi.org\/10.1002\/ijc.33592","journal-title":"Int J Cancer"},{"key":"7647_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2022.100459","volume":"37","author":"F Pantano","year":"2022","unstructured":"Pantano F, Tramontana F, Iuliani M, Leanza G, Simonetti S, Piccoli A, Paviglianiti A, Cortellini A, Spinelli GP, Longo UG, Strollo R, Vincenzi B, Tonini G, Napoli N, Santini D (2022) Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: an exploratory analysis. J Bone Oncol 37:100459. https:\/\/doi.org\/10.1016\/j.jbo.2022.100459","journal-title":"J Bone Oncol"},{"key":"7647_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000398","author":"C Ye","year":"2024","unstructured":"Ye C, Zhao B, Leslie WD, Ruiz JI, Zhao H, Abdel-Wahab N, Suarez-Almazor ME (2024) Increase in major osteoporotic fractures after therapy with immune checkpoint inhibitors. BMJ Oncol. https:\/\/doi.org\/10.1136\/bmjonc-2024-000398","journal-title":"BMJ Oncol"},{"key":"7647_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1199031","volume":"14","author":"H Liu","year":"2023","unstructured":"Liu H, Li Y, Li J, Zhang Q, Wu J, Li X, Meng L, Cao S, Li H (2023) Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study. Front Pharmacol 14:1199031. https:\/\/doi.org\/10.3389\/fphar.2023.1199031","journal-title":"Front Pharmacol"},{"key":"7647_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1332303","volume":"15","author":"J Lou","year":"2024","unstructured":"Lou J, Gong B, Li Y, Guo Y, Li L, Wang J, Liu W, You Z, Zhang H, Pan F, Liang B, Yang L, Zhou G (2024) Bone mineral density as an individual prognostic biomarker in NSCLC patients treated with immune checkpoint inhibitors. Front Immunol 15:1332303. https:\/\/doi.org\/10.3389\/fimmu.2024.1332303","journal-title":"Front Immunol"},{"issue":"2","key":"7647_CR13","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1359\/jbmr.2001.16.2.328","volume":"16","author":"MN Weitzmann","year":"2001","unstructured":"Weitzmann MN, Cenci S, Rifas L, Haug J, Dipersio J, Pacifici R (2001) T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J Bone Miner Res 16(2):328\u2013337. https:\/\/doi.org\/10.1359\/jbmr.2001.16.2.328","journal-title":"J Bone Miner Res"},{"key":"7647_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00236","volume":"10","author":"M Ponzetti","year":"2019","unstructured":"Ponzetti M, Rucci N (2019) Updates on osteoimmunology: what\u2019s new on the cross-talk between bone and immune system. Front Endocrinol (Lausanne) 10:236. https:\/\/doi.org\/10.3389\/fendo.2019.00236","journal-title":"Front Endocrinol (Lausanne)"},{"key":"7647_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.988365","volume":"14","author":"VC Brom","year":"2023","unstructured":"Brom VC, Strauss AC, Sieberath A, Salber J, Burger C, Wirtz DC, Schildberg FA (2023) Agonistic and antagonistic targeting of immune checkpoint molecules differentially regulate osteoclastogenesis. Front Immunol 14:988365. https:\/\/doi.org\/10.3389\/fimmu.2023.988365","journal-title":"Front Immunol"},{"issue":"6","key":"7647_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23223","volume":"34","author":"XP Cai","year":"2020","unstructured":"Cai XP, Zhao Q, Guo ZD, Lin SJ, Chen ZX, Chen MY, Zheng L, Zhao KW (2020) Potential diagnostic value of PD-1 in peripheral blood mononuclear cells of postmenopausal osteoporosis patients. J Clin Lab Anal 34(6):e23223. https:\/\/doi.org\/10.1002\/jcla.23223","journal-title":"J Clin Lab Anal"},{"issue":"12","key":"7647_CR17","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","volume":"23","author":"A Diez-Perez","year":"2012","unstructured":"Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR, Eastell R, Eriksen EF, Gonzalez-Macias J, Liberman UA, Wahl DA, Seeman E, Kanis JA, Cooper C, IOF CSA Inadequate Responders Working Group (2012) Treatment failure in osteoporosis. Osteoporos Int 23(12):2769\u20132774. https:\/\/doi.org\/10.1007\/s00198-012-2093-8","journal-title":"Osteoporos Int"},{"key":"7647_CR18","doi-asserted-by":"publisher","unstructured":"Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine Society (2024) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 109(10):e1991. https:\/\/doi.org\/10.1210\/clinem\/dgae373","DOI":"10.1210\/clinem\/dgae373"},{"issue":"9321","key":"7647_CR19","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(02)08761-5","volume":"359","author":"JA Kanis","year":"2002","unstructured":"Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359(9321):1929\u20131936. https:\/\/doi.org\/10.1016\/S0140-6736(02)08761-5","journal-title":"Lancet"},{"issue":"12","key":"7647_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1480301","volume":"7","author":"A Liede","year":"2018","unstructured":"Liede A, Hernandez RK, Wade SW, Bo R, Nussbaum NC, Ahern E, Dougall WC, Smyth MJ (2018) An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer. Oncoimmunology 7(12):e1480301. https:\/\/doi.org\/10.1080\/2162402X.2018.1480301","journal-title":"Oncoimmunology"},{"issue":"7","key":"7647_CR21","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1172\/JCI133334","volume":"130","author":"K Wang","year":"2020","unstructured":"Wang K, Gu Y, Liao Y, Bang S, Donnelly CR, Chen O, Tao X, Mirando AJ, Hilton MJ, Ji RR (2020) PD-1 blockade inhibits osteoclast formation and murine bone cancer pain. J Clin Invest 130(7):3603\u20133620. https:\/\/doi.org\/10.1172\/JCI133334","journal-title":"J Clin Invest"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07647-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07647-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07647-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T21:03:48Z","timestamp":1758747828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07647-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,10]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["7647"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07647-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,10]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments. This is a retrospective study, following the No: 386\/24.05.2022 approval of the hospital\u2019s IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"HG has received grants and personal fees by Roche, BMS, MSD, Novartis, and personal fees by Amgen and Pierre Fabre, outside the submitted work; all other authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}